Ultragenyx (RARE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.62B
Last updated: Nov 17, 2026 at 4:37 PM ET
Ultragenyx (RARE) Statistics
Ultragenyx (RARE) has a market cap of $1.62B and an enterprise value of $1.47B. It kept -71.69% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 9.26% below the market cap, as cash exceeds debt.
| Market Cap | $1.62B |
|---|---|
| Enterprise Value | $1.47B |
| Latest price (Nov 17, 2026) | $16.70 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 2.3x. Its year-end P/S ranged from 3.4x to 765.1x from 2017 to 2025.
| P/S Ratio | 2.3x |
|---|---|
| Forward P/S | 2.1x |
Price Statistics
The stock is down 49.52% over 52 weeks and trades 8.87% above its 50-day average.
| Beta (1Y) | 1.34 |
|---|---|
| 52-Week Change | -49.52% |
| 1-Month Change | +10.82% |
| 3-Month Change | -36.36% |
| 6-Month Change | -25.61% |
| 5-Year Change | -80.82% |
| 10-Year Change | -72.71% |
| Total Return (1Y) | -49.52% |
| Total Return (3Y CAGR) | -25.24% |
| Total Return (5Y CAGR) | -26.43% |
| Return vs SPY (1Y) | -60.69% |
| Max Drawdown (1Y) | -64.75% |
| Max Drawdown (3Y) | -78.30% |
| Sharpe Ratio (1Y) | -0.70 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $15.34 |
| 200-Day Average | $22.45 |
| 52-Week Range | $12.73 to $39.89 |
| RSI (14 Days) | 53.8 |
| Average Volume (20 Days) | 3.74M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.40x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.40x |
|---|---|
| Quick Ratio | 1.25x |
| Debt / Equity | 0.00x |
| Interest Coverage | -5.67x |
Returns and Efficiency
| Return on Assets (ROA) | -44.11% |
|---|---|
| Return on Capital Employed (ROCE) | -58.55% |
| ROA (5Y Average) | -38.34% |
| ROIC (5Y Average) | 667.50% |
| Asset Turnover | 0.61x |
| Inventory Turnover | 2.12x |
| Receivables Turnover | 3.99x |
| Cash Conversion Cycle | 141 days |
Scores
RARE has an Altman Z-Score of -5.68, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.68 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $730.28M over the last 12 months is up 15.80% from the 12 months before.
| Revenue | $730.28M |
|---|---|
| Revenue Growth (YoY) | +15.80% |
| Gross Profit | $604.93M |
| Operating Income | -$467.28M |
| Pretax Income | -$529.69M |
| Net Income | -$523.56M |
| EBITDA | -$434.95M |
| EBIT | -$467.22M |
| Reported EPS (TTM) | -$4.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $150.00M |
|---|---|
| Total Debt | $0 |
| Net Cash | $150.00M |
| Net Cash Per Share | $1.47 |
| Working Capital | $155.00M |
| Shareholder Equity | -$376.00M |
| Tangible Book Value | -$590.00M |
| Total Assets | $1.19B |
| Total Liabilities | $1.56B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.94M of capital spending, operating cash flow left -$441.77M of free cash flow.
| Operating Cash Flow | -$436.83M |
|---|---|
| Capital Expenditures | $4.94M |
| Free Cash Flow | -$441.77M |
| FCF Per Share | -$4.48 |
| Depreciation and Amortization | $35.30M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -63.99%.
| Gross Margin | 82.84% |
|---|---|
| Operating Margin | -63.99% |
| Pretax Margin | -72.53% |
| Net Margin | -71.69% |
| EBITDA Margin | -59.56% |
| EBIT Margin | -63.98% |
| FCF Margin | -60.49% |
| Gross Margin (5Y Average) | 89.47% |
Growth
Revenue grew 22.81% a year over 3 years.
| Revenue Growth (3Y CAGR) | +22.81% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.95% |
Dividends and Yields
RARE does not pay a dividend. Its free cash flow yield is -25.91%.
| FCF Yield | -25.91% |
|---|---|
| Buyback Yield | -0.13% |
| Shareholder Yield | -0.13% |
Peer Position
Against 11 similar companies, RARE has the 9th highest P/S.
P/S RatioPeer median 6.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +33.55%
| P/S Ratio | 2.3x vs 6.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +15.80% vs +33.55% median |
Analyst Forecast
Consensus estimates put revenue growth at 20.61% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +20.61% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RARE
What is RARE's market cap?
Ultragenyx has a market cap of $1.62B. Its enterprise value, which adds debt and subtracts cash, is $1.47B.
How many shares of RARE are outstanding?
Ultragenyx has 102.10M shares outstanding. The count is up 2.30% from a year earlier.
Does RARE pay a dividend?
No. Ultragenyx does not pay a dividend.
How much debt does RARE have?
Ultragenyx has $0 of total debt and $150.00M of cash and equivalents, a net cash position of $150.00M.
RARE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors